|
|
Biotech
|
|
||
Snips & notes$BOLD Audentes Therapeutics $BOLD PT Raised to $48 at SVB Leerink H.C. Wainwright / $WVE: Systemic Therapy of DMD With Stereopure PS-ASO's Remains Uncertain; Removing From Our Model and Lowering Target to $33 $CASI CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics BofA/Merrill initiates; $ACB at Buy, PT C$15. $CRON at Underperform, PT C$17. $CGC at Buy, PT C$70. $HEXO at Buy, PT C$14 $MRTX initiated at Neutral at JPMorgan. PT $72 $TXMD Announces Commercial Availability of BIJUVA in the U.S. $TPTX Turning Point Therapeutics prices #IPO. 9.25M shares at $18/share
BMO $BMY 1Q19 should meet or modestly exceed consensus expectations. IO franchise should be in line ($2.2Bn), while Eliquis is likely to beat because of lower price headwinds in first half. IO franchise will need positive 1L-NSCLC data soon to grow remain positive about upcoming trials (CM-227 part-2 and CM-9LA) $BMY+ $CELG merger seems very likely to close in 3Q19; we value the combined company at $65/share (vs. a BMY standalone valuation of $56/share) and see significant upside ($72/share). BMY remains our top value pick. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
27132 | Re: Snips & notes | minxmrphd | 2 | 4/17/2019 8:06:26 AM |